This secondary analysis of the INKeD-PC trial (n=15) found that three doses of intranasal racemic ketamine in patients with advanced cancer receiving palliative care led to clinically meaningful improvements in existential distress, anxiety, symptom burden, and quality of life, with psychological symptoms improving more than physical ones.
- Published
- Journal
- Journal of Pain and Symptom Management
- Authors
- Aguiar, S., Makarious, M., Lipsitz, O., deVries, F. E., Doyle, Z., McIntyre, R. S., Rodin, G., Zimmermann, C., Mak, E., Hannon, B., Schulz-Quach, C., Al Kindy, A., Patel, Z., Rosenblat, J. D., Li, M.